SOD1 and amyotrophic lateral sclerosis: However, Tofersen administration in patients with SOD1 ALS was shown to only reduce SOD1 levels in cerebrospinal fluid by approximately one-third, indicating a large pool of mutant SOD1 escapes ASO-mediated degradation, is continually translated and likely causes continual toxicity.